Login to Your Account



FTC Looks to Court, Congress to Outlaw Pay-for-Delay Deals

By Mari Serebrov
Washington Editor

Tuesday, March 26, 2013
Adamant that pay-for-delay settlements between brand- and generic drugmakers are anticompetitive, the FTC is leaving no stone unturned in its efforts to get the settlements outlawed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription